Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Arun RajanChristopher R HeeryAnish ThomasAndrew L MammenSusan PerryGeraldine O'Sullivan CoyneUdayan GuhaArlene BermanEva SzaboRavi A MadanLeomar Y BallesterStefania PittalugaRenee N DonahueYo-Ting TsaiLauren M LeponeKevin ChinFiona GintyAnup SoodStephen M HewittJeffrey SchlomRaffit HassanJames L GulleyPublished in: Journal for immunotherapy of cancer (2019)
ClinicalTrials.gov - NCT01772004 . Date of registration - January 21, 2013.